Bleeding Related to Disturbed Fibrinolysis

Overview

Journal Br J Haematol

Specialty Hematology

Date 2016 Aug 2

PMID 27477022

Citations 43

Authors

Krasimir Kolev

Colin Longstaff

Affiliations

Soon will be listed here.

Abstract

The components and reactions of the fibrinolysis system are well understood. The pathway has fewer reactants and interactions than coagulation, but the generation of a complete quantitative model is complicated by the need to work at the solid-liquid interface of fibrin. Diagnostic tools to detect disease states due to malfunctions in the fibrinolysis pathway are also not so well developed as is the case with coagulation. However, there are clearly a number of inherited or acquired pathologies where hyperfibrinolysis is a serious, potentially life-threatening problem and a number of antifibrinolytc drugs are available to treat hyperfibrinolysis. These topics will be covered in the following review.

Citing Articles

Harnessing micrometer-scale tPA beads for high plasmin generation and accelerated fibrinolysis.

Osmond M, Dabertrand F, Quillinan N, Su E, Lawrence D, Marr D bioRxiv. 2024; .

PMID: 39574757 PMC: 11580863. DOI: 10.1101/2024.11.06.621942.

[The golden approach to trauma. Which blood products are needed for optimization of prehospital trauma care?].

Bamberg M, Grasshoff C, Gerstner J, Boos M, Bentele M, Viergutz T Anaesthesiologie. 2024; 73(12):819-828.

PMID: 39557666 PMC: 11614957. DOI: 10.1007/s00101-024-01482-6.

A Protease from Moringa oleifera Lam. Exhibits In-vitro Blood Clot Solubilization and Fibrin Hydrolysis.

Sawetaji , Aggarwal K Protein J. 2024; 43(4):923-934.

PMID: 39068632 DOI: 10.1007/s10930-024-10222-z.

Case report: Chronic disseminated intravascular coagulopathy with concurrent paraneoplastic secondary hyperfibrinolysis in a dog with metastatic nasal adenocarcinoma.

Granger Jr K, Paulos T, Boss M, Guieu L, Shropshire S Front Vet Sci. 2024; 11:1375507.

PMID: 38840638 PMC: 11152169. DOI: 10.3389/fvets.2024.1375507.

Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A.

Strilchuk A, Hur W, Batty P, Sang Y, Abrahams S, Yong A Sci Transl Med. 2024; 16(735):eadh0027.

PMID: 38381848 PMC: 11293256. DOI: 10.1126/scitranslmed.adh0027.

References

Sinniger V, Merton R, Fabregas P, Felez J, Longstaff C . Regulation of tissue plasminogen activator activity by cells. Domains responsible for binding and mechanism of stimulation. J Biol Chem. 1999; 274(18):12414-22. DOI: 10.1074/jbc.274.18.12414. View

Varju I, Tenekedjiev K, Keresztes Z, Pap A, Szabo L, Thelwell C . Fractal kinetic behavior of plasmin on the surface of fibrin meshwork. Biochemistry. 2014; 53(40):6348-56. DOI: 10.1021/bi500661m. View

Mann K, Freeman K . TACTIC: Trans-Agency Consortium for Trauma-Induced Coagulopathy. J Thromb Haemost. 2015; 13 Suppl 1:S63-71. PMC: 4498273. DOI: 10.1111/jth.12981. View

Longstaff C . Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coagul Fibrinolysis. 1994; 5(4):537-42. View

Gunawan B, Runyon B . The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Aliment Pharmacol Ther. 2006; 23(1):115-20. DOI: 10.1111/j.1365-2036.2006.02730.x. View

van Geffen M, Heerde W . Global haemostasis assays, from bench to bedside. Thromb Res. 2012; 129(6):681-7. DOI: 10.1016/j.thromres.2011.12.006. View

Roberts L, Patel R, Arya R . Haemostasis and thrombosis in liver disease. Br J Haematol. 2009; 148(4):507-21. DOI: 10.1111/j.1365-2141.2009.08021.x. View

Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C . The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2012; 11(2):307-14. DOI: 10.1111/jth.12078. View

Ajzner E, Schlammadinger A, Kerenyi A, Bereczky Z, Katona E, Haramura G . Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood. 2008; 113(3):723-5. DOI: 10.1182/blood-2008-09-179333. View

10.

Spahn D, Bouillon B, Cerny V, Coats T, Duranteau J, Fernandez-Mondejar E . Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013; 17(2):R76. PMC: 4056078. DOI: 10.1186/cc12685. View

11.

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D . Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. Hematol Oncol. 2008; 26(4):241-6. PMC: 3496178. DOI: 10.1002/hon.867. View

12.

Perouansky M, OPPENHEIM A, Sprung C, Eidelman L, Pizov R . Effect of haemofiltration on pathological fibrinolysis due to severe sepsis: a case report. Resuscitation. 1999; 40(1):53-6. DOI: 10.1016/s0300-9572(99)00002-7. View

13.

Maino A, Garagiola I, Artoni A, Al-Humood S, Peyvandi F . A novel mutation of alpha2-plasmin inhibitor gene causes an inherited deficiency and a bleeding tendency. Haemophilia. 2007; 14(1):166. DOI: 10.1111/j.1365-2516.2007.01588.x. View

14.

Taylor Jr F, Toh C, Hoots W, Wada H, Levi M . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2002; 86(5):1327-30. View

15.

Marder V, Stewart D . Towards safer thrombolytic therapy. Semin Hematol. 2002; 39(3):206-16. DOI: 10.1053/shem.2002.34088. View

16.

Anwar R, Miloszewski K . Factor XIII deficiency. Br J Haematol. 1999; 107(3):468-84. DOI: 10.1046/j.1365-2141.1999.01648.x. View

17.

Lee C, Mann K . Activation/inactivation of human factor V by plasmin. Blood. 1989; 73(1):185-90. View

18.

Royston D, Bidstrup B, Taylor K, Sapsford R . Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987; 2(8571):1289-91. DOI: 10.1016/s0140-6736(87)91190-1. View

19.

Tutwiler V, Litvinov R, Lozhkin A, Peshkova A, Lebedeva T, Ataullakhanov F . Kinetics and mechanics of clot contraction are governed by the molecular and cellular composition of the blood. Blood. 2015; 127(1):149-59. PMC: 4705605. DOI: 10.1182/blood-2015-05-647560. View

20.

Blavignac J, Bunimov N, Rivard G, Hayward C . Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment. Semin Thromb Hemost. 2011; 37(6):713-20. DOI: 10.1055/s-0031-1291382. View